A new, simple, and microwave-assisted, solution-phase T3P Ò -DMSO mediated method for the preparation of a novel class of estrogen receptor alpha (ERa) ligands based on the 2-phenylquinoline scaffold was developed. Furthermore, the novel ERa ligands were tested for their bioactivity against ERa-positive and ERa-negative cell lines. The ligand (entry 4), with amine and nitro group substitution at C4 position, displayed significant cytotoxicity against MCF-7 and HepG2 cells with an IC 50 value of 6 and 11 lM, respectively. On the other hand, ERa-negative cells displayed resistance to quinolines induced cytotoxicity with an IC 50 value >100 Mm and they does not induce cytotoxicity in normal breast epithelial cells. Molecular docking analyses suggest a consistent binding mode for these ERa ligands in the ligand binding domain of the human ERa and predict the ligands to occupy the hydrophobic cavity in a similar fashion as estradiol or GW2368.
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Breast cancer is a leading cancer in women worldwide and contributing to second cause of lethality after lung cancer. 1, 2 Most breast cancers are associated with interaction of estrogen receptors (ER) in the breast epithelial cells to estrogen. The physiological action of estrogen is induced via two types of estrogen receptors namely ERa and ERb. 3 Research in the previous decade revealed that more than 70% of breast cancers are due to ERa dependent epithelial cell proliferation. The role of ERb is not clear in initiation and progression of breast cancer. 4 ERa belongs to nuclear receptor superfamily which regulates the transcription of genes involved in proliferation, anti-apoptosis, metastasis and immunosurveillance. [5] [6] [7] The binding of 17b-estradiol to ERa induces the receptor dimerization and facilitates binding of the ligand-receptor complex to the promoter of target genes. 8 Also, ER-dependent pathways regulate the synthesis and distribution of glycosaminoglycans in cancer cells. 9 Several small molecule ERa antagonists including Tamoxifen, Raloxifene and Fulvestrant have been implemented in the treatment of breast cancer. 10, 11 Benzisoxazole tethered azoles have known to be the better ER ligands. [12] [13] [14] Therefore, probing small molecules against ERa is considered to be the most attractive therapeutic target to treat breast cancer ( Fig. 1 ). 15 Quinoline derivatives are the pharmacologically important heterocycles which have been studied extensively for their anticancer properties. Multiple reports have demonstrated the preparation of quinolines using strong base like tertiary butoxide. 16, 17 We previous reported the anti-cancer effect of various heterocyclic compounds [18] [19] [20] and recently reported the solution phase synthesis of 2-amino-chromene-3-carbonitriles from alcohols, malanonitrile and phenols. 21 Using a similar strategy, herein, we report a simple and efficient method for the preparation of T3P Ò -DMSO mediated 2-phenylquinoline derivatives using amino alcohols and acetophenones under microwave irradiation and evaluated for their cytotoxicity. The newly developed method was generalized using variety of aromatic 2-amino alcohols and Table 1 ). Our docking analysis validated the interaction of quinoline derivatives with the estrogen receptor in the similar fashion as estradiol to induce its anticancer effect.
Additionally, all the new molecules were characterized completely using IR, 1 H NMR, 13 C NMR, and LC-MS spectral analysis (please refer Supplementary data).
Further, the library of ERa ligands was tested for its cytotoxicity against ERa-positive, ERa-negative cancer cells and their counterpart non-diseased breast epithelial cells as described previously and detailed methodology is provided in Supplementary information. 22, 23 The results are summarized in Table 2 .
Among the tested compounds 4, 6, and 10 significantly inhibited the proliferation of ERa-positive cells. Further, compounds (4, 6, and 10) with high cytotoxicity were tested against ERa-negative cells. All the ERa-negative cells were resistance to the lead compounds with IC 50 values more than 100 lM. However, the shortlisted three molecules did not induce cytotoxicity on MCF-10A cells up to 72 h at 100 lM. These results indicate that the newly synthesized ERa ligands are selectively cytotoxic against ERa expressing cancer cells and does not interfere with viability of their counterpart.
Additionally, the structural models for molecular interactions between the newer ERa ligands and the human estrogen receptor were generated using in silico docking analysis as described previously and detailed methodology is provided in Supplementary information. [24] [25] [26] Docking was based on the co-crystal structure of the naphthalene derivative GW2368 with the estrogen receptor (PDB: 3DT3). 27 Molecular docking suggests a consistent binding mode for the series of quinoline-based ERa ligands in the ligand binding domain of the human estrogen receptor. Thereby, the compounds occupy the hydrophobic cavity in a similar fashion as estradiol or GW2368 (Fig. 2) . The docking scores of the ERa ligands were comparable with estradiol or GW2368 (Supplementary Table 1 ). The quinoline scaffold of the ERa ligands occupies the position of rings A and B in the steroid and show major overlap with the naphthalene ring system of GW2368. Furthermore, presence of benzene substituents allows for interactions with His-524 in agreement with other estrogen receptor ligands. Presence of a hydrogen bond donor function is predicted to facilitate a second binding mode, where hydrogen bonds to Arg-394 and Glu-353 are formed. The structure-activity-relationship studies for the compound 4, which bearing chlorine atom at R 2 renders significant anti-proliferative activity towards ER positive cancer cells, whereas the presence of methyl group at R 1 decreases the activity. This observation was evidenced with strong binding of compound 4 to ER alpha LBD, when compared to compound 8.
In conclusion, we have identified a novel quinoline-based ERa ligands as biologically active compounds against ERa expressing human cancer cells. This study also introduces a novel microwave-assisted synthesis pathway to the compound series. Therefore, method will be useful to develop libraries of quinoline-based ERa ligands to treat breast cancer.
